Remdesivir for the treatment of COVID-19.
Grundeis F, Ansems K, Dahms K, Thieme V, Metzendorf MI, Skoetz N, Benstoem C, Mikolajewska A, Griesel M, Fichtner F, Stegemann M.
Grundeis F, et al.
Cochrane Database Syst Rev. 2023 Jan 25;1(1):CD014962. doi: 10.1002/14651858.CD014962.pub2.
Cochrane Database Syst Rev. 2023.
PMID: 36695483
Free PMC article.
Review.
We differentiated between non-hospitalised individuals with asymptomatic SARS-CoV-2 infection or mild COVID-19 and hospitalised individuals with moderate to severe COVID-19. ...AUTHORS' CONCLUSIONS: Based on the available evidence up to 31 May 2022, remdesivir proba …
We differentiated between non-hospitalised individuals with asymptomatic SARS-CoV-2 infection or mild COVID-19 and hospitalised indiv …